ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3024% above fair value
$1443.50+16.22 (+1.14%)
Close on Nov 13, 2026Market cap $1.36TP/E 46.9Yield 0.43%
Eli Lilly total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Eli Lilly's total debt was $49.50B at Sep 30, 2026. For fiscal 2025 it was $42.50B, up 26.3% from the year before. Over ten years it grew 18.2% a year on average. The highest annual figure on record is $42.50B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.50B | +26.3% |
| FY2024 | Dec 31, 2024 | $33.64B | +33.4% |
| FY2023 | Dec 31, 2023 | $25.23B | +55.3% |
| FY2022 | Dec 31, 2022 | $16.24B | -3.8% |
| FY2021 | Dec 31, 2021 | $16.88B | +1.7% |
| FY2020 | Dec 31, 2020 | $16.60B | +8.3% |
| FY2019 | Dec 31, 2019 | $15.32B | +48.7% |
| FY2018 | Dec 31, 2018 | $10.30B | -24.5% |
| FY2017 | Dec 31, 2017 | $13.65B | +32.4% |
| FY2016 | Dec 31, 2016 | $10.31B | +29.2% |
| FY2015 | Dec 31, 2015 | $7.98B | -0.5% |
| FY2014 | Dec 31, 2014 | $8.02B | +53.9% |
| FY2013 | Dec 31, 2013 | $5.21B | -5.8% |
| FY2012 | Dec 31, 2012 | $5.53B | -35.0% |
| FY2011 | Dec 31, 2011 | $8.50B | +22.5% |
| FY2010 | Dec 31, 2010 | $6.94B | +4.6% |
| FY2009 | Dec 31, 2009 | $6.64B | -36.5% |
| FY2008 | Dec 31, 2008 | $10.46B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $49.50B | +16.5% |
| Q2 FY2026 | Jun 30, 2026 | $54.91B | +37.6% |
| Q1 FY2026 | Mar 31, 2026 | $43.37B | +12.6% |
| Q4 FY2025 | Dec 31, 2025 | $42.50B | +26.3% |
| Q3 FY2025 | Sep 30, 2025 | $42.51B | +36.6% |
| Q2 FY2025 | Jun 30, 2025 | $39.90B | +38.1% |
| Q1 FY2025 | Mar 31, 2025 | $38.52B | +46.9% |
| Q4 FY2024 | Dec 31, 2024 | $33.64B | +33.4% |
| Q3 FY2024 | Sep 30, 2024 | $31.12B | +54.3% |
| Q2 FY2024 | Jun 30, 2024 | $28.89B | +53.5% |
| Q1 FY2024 | Mar 31, 2024 | $26.21B | +38.8% |
| Q4 FY2023 | Dec 31, 2023 | $25.23B | +55.3% |
| Q3 FY2023 | Sep 30, 2023 | $20.17B | +26.9% |
| Q2 FY2023 | Jun 30, 2023 | $18.82B | +11.9% |
| Q1 FY2023 | Mar 31, 2023 | $18.88B | +14.4% |
| Q4 FY2022 | Dec 31, 2022 | $16.24B | -3.8% |
| Q3 FY2022 | Sep 30, 2022 | $15.89B | -7.0% |
| Q2 FY2022 | Jun 30, 2022 | $16.81B | +1.8% |
| Q1 FY2022 | Mar 31, 2022 | $16.51B | +1.9% |
| Q4 FY2021 | Dec 31, 2021 | $16.88B | +1.7% |
| Q3 FY2021 | Sep 30, 2021 | $17.09B | +1.0% |
| Q2 FY2021 | Jun 30, 2021 | $16.52B | +1.1% |
| Q1 FY2021 | Mar 31, 2021 | $16.20B | -6.0% |
| Q4 FY2020 | Dec 31, 2020 | $16.60B | +8.3% |
| Q3 FY2020 | Sep 30, 2020 | $16.92B | +11.1% |
| Q2 FY2020 | Jun 30, 2020 | $16.33B | +3.4% |
| Q1 FY2020 | Mar 31, 2020 | $17.23B | +7.9% |
| Q4 FY2019 | Dec 31, 2019 | $15.32B | +48.7% |
| Q3 FY2019 | Sep 30, 2019 | $15.23B | +20.1% |
| Q2 FY2019 | Jun 30, 2019 | $15.79B | +29.2% |
| Q1 FY2019 | Mar 31, 2019 | $15.97B | +36.5% |
| Q4 FY2018 | Dec 31, 2018 | $10.30B | -24.5% |
| Q3 FY2018 | Sep 30, 2018 | $12.68B | -5.9% |
| Q2 FY2018 | Jun 30, 2018 | $12.22B | -0.8% |
| Q1 FY2018 | Mar 31, 2018 | $11.70B | +14.2% |
| Q4 FY2017 | Dec 31, 2017 | $13.65B | +32.4% |
| Q3 FY2017 | Sep 30, 2017 | $13.46B | – |
| Q2 FY2017 | Jun 30, 2017 | $12.31B | – |
| Q1 FY2017 | Mar 31, 2017 | $10.25B | – |
| Q4 FY2016 | Dec 31, 2016 | $10.31B | – |
See a number that looks wrong?